4D Molecular Therapeutics (FDMT) Financials

The income statement of 4D Molecular Therapeutics, Inc. (FDMT) provides a snapshot of the company's financial performance over a specific period. It outlines the revenue generated by the company and deducts the cost of goods sold to determine the gross profit. Operating expenses, such as research and development costs and general administrative expenses, are then subtracted from the gross profit to arrive at the earnings before interest and taxes (EBIT). This figure reflects the company's profitability before considering interest expenses and taxes. EBITDA, or earnings before interest, taxes, depreciation, and amortization, is a similar measure that adds back depreciation and amortization expenses to the EBIT.

The gross profit of 4D Molecular Therapeutics, Inc. (FDMT) is the difference between its total revenue and the cost of goods sold. It represents the amount of money the company earns from its core operations after accounting for direct costs. Gross profit is an essential metric to assess a company's profitability and efficiency in its production processes. Net income from stockholders, on the other hand, is the profit attributable to the company's equity holders after deducting taxes, interest, and other expenses. It is an indicator of the company's profitability from the perspective of its investors.